JP2022518282A - 抗ｃｄ３８結合ドメイン - Google Patents

抗ｃｄ３８結合ドメイン Download PDF

Info

Publication number
JP2022518282A
JP2022518282A JP2021543170A JP2021543170A JP2022518282A JP 2022518282 A JP2022518282 A JP 2022518282A JP 2021543170 A JP2021543170 A JP 2021543170A JP 2021543170 A JP2021543170 A JP 2021543170A JP 2022518282 A JP2022518282 A JP 2022518282A
Authority
JP
Japan
Prior art keywords
seq
sequence
domain
composition
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021543170A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518282A5 (https=
JPWO2020154540A5 (https=
Inventor
キャスリーン アン イライアス，
グレゴリー ランデス，
シュウェタ シン，
ウーター コーバー，
アンドリュー ウォリング ドレイク，
メアリー ハーク－フレンドショー，
ヴィナイ バスカー，
エリン ウィレルト，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2022518282A publication Critical patent/JP2022518282A/ja
Publication of JP2022518282A5 publication Critical patent/JP2022518282A5/ja
Publication of JPWO2020154540A5 publication Critical patent/JPWO2020154540A5/ja
Priority to JP2024229904A priority Critical patent/JP2025060876A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Finish Polishing, Edge Sharpening, And Grinding By Specific Grinding Devices (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Gas Separation By Absorption (AREA)
JP2021543170A 2019-01-23 2020-01-23 抗ｃｄ３８結合ドメイン Withdrawn JP2022518282A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024229904A JP2025060876A (ja) 2019-01-23 2024-12-26 抗ｃｄ３８結合ドメイン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795855P 2019-01-23 2019-01-23
US62/795,855 2019-01-23
PCT/US2020/014845 WO2020154540A1 (en) 2019-01-23 2020-01-23 Anti-cd38 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024229904A Division JP2025060876A (ja) 2019-01-23 2024-12-26 抗ｃｄ３８結合ドメイン

Publications (3)

Publication Number Publication Date
JP2022518282A true JP2022518282A (ja) 2022-03-14
JP2022518282A5 JP2022518282A5 (https=) 2023-02-01
JPWO2020154540A5 JPWO2020154540A5 (https=) 2023-02-01

Family

ID=69740548

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021543170A Withdrawn JP2022518282A (ja) 2019-01-23 2020-01-23 抗ｃｄ３８結合ドメイン
JP2024229904A Pending JP2025060876A (ja) 2019-01-23 2024-12-26 抗ｃｄ３８結合ドメイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024229904A Pending JP2025060876A (ja) 2019-01-23 2024-12-26 抗ｃｄ３８結合ドメイン

Country Status (9)

Country Link
US (2) US11414496B2 (https=)
EP (1) EP3914358A1 (https=)
JP (2) JP2022518282A (https=)
CN (1) CN113710324B (https=)
AR (1) AR119677A1 (https=)
AU (1) AU2020211407A1 (https=)
CA (1) CA3127624A1 (https=)
TW (1) TWI863959B (https=)
WO (1) WO2020154540A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113454108B (zh) 2019-01-23 2025-02-14 米伦纽姆医药公司 包含去免疫化志贺菌毒素a亚基效应子的cd38结合蛋白
AR119677A1 (es) 2019-01-23 2022-01-05 Millennium Pharm Inc Dominios de unión anti-cd38
CA3180690A1 (en) * 2020-06-17 2021-12-23 Ahmed Mahiuddin Cd38 antibodies for treatment of human diseases
WO2023172983A1 (en) * 2022-03-08 2023-09-14 Molecular Templates, Inc. Ctla-4 binding molecules comprising shiga toxin a subunit scaffolds and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509187A (ja) * 2010-12-30 2014-04-17 武田薬品工業株式会社 結合抗ｃｄ３８抗体
JP2016522816A (ja) * 2013-04-29 2016-08-04 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
WO2018083126A1 (en) * 2016-11-01 2018-05-11 Genmab B.V. Polypeptide variants and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US7139665B2 (en) 2002-02-27 2006-11-21 California Institute Of Technology Computational method for designing enzymes for incorporation of non natural amino acids into proteins
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
EP1675620B1 (en) 2003-10-09 2019-05-08 Ambrx, Inc. Polymer derivatives
EP2327724A3 (en) 2004-02-02 2011-07-27 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7887801B2 (en) 2007-07-13 2011-02-15 Topotarget Germany Ag Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
RS60280B1 (sr) 2013-03-12 2020-06-30 Molecular Templates Inc Citotoksični proteini koji sadrže ciljane vezujuće regione za ćelije i regioni shiga toksina a podjedinice za selektivno ubijanje određenih vrsta ćelija
US20160177284A1 (en) 2014-01-27 2016-06-23 Molecular Templates, Inc. Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
CN111909278B (zh) 2014-01-27 2024-04-09 分子模板公司 Mhc i类表位递送多肽
WO2017019623A2 (en) 2015-07-26 2017-02-02 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
ES2723774T3 (es) 2014-03-11 2019-09-02 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
AU2015229583B2 (en) 2014-03-11 2020-07-09 Molecular Templates, Inc. Proteins comprising amino-terminal proximal Shiga toxin A Subunit effector regions and cell-targeting immunoglobulin-type binding regions
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
ES2919749T3 (es) 2014-06-11 2022-07-28 Molecular Templates Inc Moléculas dirigidas a células citotóxicas resistentes a la escisión por proteasa
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
MX2017010072A (es) 2015-02-05 2017-11-09 Molecular Templates Inc Moleculas multivalentes que se enlazan a cd20, las cuales comprenden regiones efectoras de la subunidad a de la toxina shiga, y composiciones enriquecidas de las mismas.
AU2016271124C1 (en) * 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
EP3573648B1 (en) 2017-01-25 2023-11-22 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
US20200190138A1 (en) 2017-02-28 2020-06-18 Chugai Seiyaku Kabushiki Kaisha Protein purification with protein l
CN113454108B (zh) * 2019-01-23 2025-02-14 米伦纽姆医药公司 包含去免疫化志贺菌毒素a亚基效应子的cd38结合蛋白
AR119677A1 (es) 2019-01-23 2022-01-05 Millennium Pharm Inc Dominios de unión anti-cd38
CN115769181B (zh) 2021-04-23 2025-10-10 京东方科技集团股份有限公司 一种解锁控制方法、装置、电子设备和计算机可读存储介质

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509187A (ja) * 2010-12-30 2014-04-17 武田薬品工業株式会社 結合抗ｃｄ３８抗体
JP2016522816A (ja) * 2013-04-29 2016-08-04 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
WO2018083126A1 (en) * 2016-11-01 2018-05-11 Genmab B.V. Polypeptide variants and uses thereof

Also Published As

Publication number Publication date
CN113710324A (zh) 2021-11-26
US11414496B2 (en) 2022-08-16
US20230203186A1 (en) 2023-06-29
AU2020211407A1 (en) 2021-08-12
JP2025060876A (ja) 2025-04-10
TW202043281A (zh) 2020-12-01
US20200231696A1 (en) 2020-07-23
US12312411B2 (en) 2025-05-27
TWI863959B (zh) 2024-12-01
AR119677A1 (es) 2022-01-05
CN113710324B (zh) 2025-02-14
EP3914358A1 (en) 2021-12-01
WO2020154540A1 (en) 2020-07-30
CA3127624A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
JP6571527B2 (ja) 二重特異性抗体
US20240343811A1 (en) Cd16 antibody and use thereof
US12312411B2 (en) Anti-CD38 binding domains
JP2019533444A (ja) ＩＬ−１５／ＩＬ−１５ＲアルファＦｃ融合タンパク質およびＰＤ−１抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質
TW202231292A (zh) 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
CN110894240A (zh) 结合cd3和肿瘤抗原的异二聚体抗体
WO2022056197A9 (en) Immune targeting molecules and uses thereof
AU2018344417A1 (en) CD3/CD33 bispecific binding molecules
CA3227854A1 (en) Novel anti-sirpa antibodies
WO2023131328A1 (zh) 一种抗体及其用途
WO2023284829A1 (zh) 特异性结合hgfr和egfr的抗原结合分子及其医药用途
KR20230154311A (ko) Cd3 및 gpc3에 결합하는 이종이량체 항체
JP2023508439A (ja) 治療ｆｃ組成物の化学誘導会合および解離ならびにｔ細胞エンゲージャーとヒト血清アルブミンとの化学誘導二量体形成
CN119546645A (zh) 特异性结合gucy2c和cd3的抗原结合分子及其医药用途
WO2023083298A1 (zh) 抗icosl抗体融合蛋白及用途
US20240239915A1 (en) Fc variant with high thermal stability and attenuated effector function
WO2026046399A1 (en) Anti-dll3 antibodies and use thereof
TW202602945A (zh) 抗ｇｕｃｙ２ｃ抗體及其多特異性抗體的用途
WO2025092742A1 (zh) 结合bcma的抗体以及包含其的多特异性抗体
JP2025532504A (ja) 抗ｉｌｔ４抗体及びその医薬的使用
TW202528360A (zh) 藉由重組反應製備異源多聚體的方法
CN119546636A (zh) FcRn-结合多肽及其用途
EP4499709A2 (en) Anti-psma antibodies, variants, and uses thereof
CN121487968A (zh) 用于调节免疫系统的分子和其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230123

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240621

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241226

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250226